Teflaro Approval and Launch
Teflaro (ceftaroline fosamil), an intravenous cephalosporin antibiotic for skin and lung infections, gained FDA approval on October 29, 2010, from Allergan (formerly Cubist Pharmaceuticals).[1] It launched commercially in 2011.
Key Patents and Exclusivity
Primary composition-of-matter patent US 6,977,274 covers Teflaro until May 23, 2027, after pediatric exclusivity extension.[2] Formulation patent US 7,919,118 expires August 9, 2022, but does not block generics alone. No new drug application (NDA) exclusivity remains; it ended around 2015.
Paragraph IV Challenges and Litigation
Mylan filed the first ANDA Paragraph IV challenge in March 2015, targeting multiple patents including '274. Allergan sued, settling in December 2018 to allow generic entry no earlier than January 1, 2023.[3] Sandoz settled similarly for 2023 entry. Lupin and Aurobindo face ongoing litigation with tentative 2027-2028 resolutions, pending court outcomes.[2]
Expected Generic Entry Dates
No generics launched as of 2024; earliest entry is January 1, 2023, from Mylan (now Viatris), delayed by settlement terms and supply issues.[4] If '274 patent holds, full generic competition starts May 2027. FDA tentative approvals exist for Mylan and others, signaling readiness post-hatch-waxman stay (30 months expired).[2]
Factors That Could Delay or Accelerate
Patent disputes at District of Delaware could extend to 2026 appeals. No pediatric exclusivity blocks ANDAs now. Biosimilar pathway does not apply (small molecule). Supply shortages or manufacturing holds might push beyond 2027.[1][2]
Market Impact and Alternatives
Generics could cut Teflaro's $100M+ annual U.S. sales by 80% post-entry. Current alternatives include vancomycin or daptomycin for similar infections; no direct cephalosporin generics compete yet.[4]
[1]: FDA Approval Letter
[2]: DrugPatentWatch.com - Teflaro Patents
[3]: Allergan-Mylan Settlement
[4]: FDA Orange Book - Ceftaroline Fosamil